For women diagnosed with ovarian cancer, genetic and biomarker testing can direct treatment and improve outcomes — but utilization remains limited.
Each year, approximately 20,000 women in the U.S. are diagnosed with ovarian cancer, the deadliest of all gynecologic cancers. Due to a lack of early detection methods, most patients receive a late-stage diagnosis, resulting in a five-year survival rate of less than 50%. In the face of these grim statistics, genetic and biomarker testing has emerged as a powerful tool to guide treatment decisions and improve patient outcomes. All women diagnosed with ovarian cancer are now recommended to receive genetic counseling, regardless of family history.
To better understand the utilization and disparities in ovarian cancer genetic testing, Komodo Health partnered with the Ovarian Cancer Research Alliance (OCRA) — the largest global organization dedicated to fighting ovarian and gynecologic cancers. OCRA funds groundbreaking research, advocates for increased federal funding, and provides vital support to patients and families navigating a diagnosis.
Our analysis found that genetic testing rates for ovarian cancer patients fall far short of the standard of care, with only 52% receiving testing despite universal recommendations. We also found that patients with commercial insurance were 37% more likely to be tested than those with public insurance, and that younger patients had significantly higher testing rates.
These findings underscore critical gaps in access that must be addressed to ensure equitable screening and treatment opportunities for all ovarian cancer patients. By leveraging real-world patient data, we can identify barriers to genetic testing and work toward eliminating disparities in ovarian cancer care. Data-driven insights like these are critical in guiding advocacy efforts, informing healthcare policies, and ensuring that every patient — regardless of age, insurance status, or background — has access to life-saving genetic testing.
To see more articles like this, follow Komodo Health on X, LinkedIn, or YouTube, and visit Insights on our website.
